文献速递前列腺癌

基于活检的基因组分类器预测中高危前列腺癌根治性放疗联合短期雄激素剥夺治疗后远处转移

Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2017-01-24

单中心研究纳入100例中危(55%)和高危(45%)前列腺癌患者,接受根治性放疗联合中位6个月雄激素剥夺治疗(ADT),评估活检22标志物基因组分类器(GC)预测远处转移的能力。GC评分每增加0.1单位与远处转移时间显著相关(HR 1.40,95%CI 1.10-1.84,P=0.006),多变量分析仍显著(校正HR 1.36,95%CI 1.04-1.83,P=0.024)。GC评分5年远处转移c指数为0.76(95%CI 0.57-0.89),GC>0.6组5年转移累积发生率高达20%(P=0.02)。

要点

  • GC评分每增加0.1单位与远处转移时间显著相关(HR 1.40,95%CI 1.10-1.84,P=0.006)。
  • GC评分5年远处转移c指数为0.76(95%CI 0.57-0.89),高于NCCN风险分组和CAPRA评分。
  • GC>0.6组5年转移累积发生率高达20%(P=0.02),尽管接受多模式治疗。

核心结论

  • 作者认为这是首次证明基于活检的GC评分能预测中高危前列腺癌根治性放疗联合ADT后的远处转移。
  • GC风险最高(GC>0.6)的患者尽管接受多模式治疗,转移率仍高,作者认为他们可能适合治疗强化和/或参加新疗法临床试验。

研究设计与样本

  • 单中心研究,纳入2001-2013年接受根治性放疗联合中位6个月ADT(范围3-39个月)的中危(55%)和高危(45%)前列腺癌患者100例,均有可用的活检组织。
  • 选取Gleason评分最高和肿瘤侵犯百分比最高的穿刺活检核心的6-10张4微米切片进行宏切割提取RNA,测定GC评分(范围0.04-0.92)。
  • 主要终点为远处转移时间,中位随访5.1年,研究期间发生18例转移。

主要发现

  • 单变量分析中,GC评分每增加0.1单位与远处转移时间显著相关(HR 1.40,95%CI 1.10-1.84,P=0.006)。
  • 多变量分析校正临床变量后,GC评分每增加0.1单位仍与远处转移时间显著相关(校正HR 1.36,95%CI 1.04-1.83,P=0.024)。
  • 5年远处转移c指数:CAPRA评分为0.45(95%CI 0.27-0.64),NCCN风险分组为0.63(95%CI 0.40-0.78),GC评分为0.76(95%CI 0.57-0.89)。
  • 采用预设GC风险分类,GC>0.6组放疗后5年转移累积发生率达20%(P=0.02)。

关键数值与推荐

  • GC评分范围0.04-0.92。
  • GC评分每增加0.1单位与远处转移时间显著相关(HR 1.40,95%CI 1.10-1.84,P=0.006)。
  • GC评分5年远处转移c指数为0.76(95%CI 0.57-0.89)。
  • GC>0.6组5年转移累积发生率为20%(P=0.02)。

临床怎么用

  • 作者认为GC风险最高(GC>0.6)的患者尽管接受多模式治疗转移率仍高,可能适合治疗强化和/或参加新疗法临床试验。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We examined the ability of a biopsy-based 22-marker genomic classifier (GC) to predict for distant metastases after radiation and a median of 6 months of androgen deprivation therapy (ADT). METHODS: We studied 100 patients with intermediate-risk (55%) and high-risk (45%) prostate cancer who received definitive radiation plus a median of 6 months of ADT (range 3-39 months) from 2001-2013 at a single center and had available biopsy tissue. Six to ten 4 micron sections of the needle biopsy core with the highest Gleason score and percentage of tumor involvement were macrodissected for RNA extraction. GC scores (range, 0.04-0.92) were determined. The primary end point of the study was time to distant metastasis. Median follow-up was 5.1 years. There were 18 metastases during the study period. RESULTS: On univariable analysis (UVA), each 0.1 unit increase in GC score was significantly associated with time to distant metastasis (hazard ratio: 1.40 (1.10-1.84), P=0.006) and remained significant after adjusting for clinical variables on multivariable analysis (MVA) (adjusted hazard ratio: 1.36 (1.04-1.83), P=0.024). The c-index for 5-year distant metastasis was 0.45 (95% confidence interval: 0.27-0.64) for Cancer of the Prostate Risk Assessment score, 0.63 (0.40-0.78) for National Comprehensive Cancer Network (NCCN) risk groups, and 0.76 (0.57-0.89) for the GC score. Using pre-specified GC risk categories, the cumulative incidence of metastasis for GC>0.6 reached 20% at 5 years after radiation (P=0.02). CONCLUSIONS: We believe this is the first demonstration of the ability of the biopsy-based GC score to predict for distant metastases after definitive radiation and ADT for intermediate- and high-risk prostate cancer. Patients with the highest GC risk (GC>0.6) had high rates of metastasis despite multi-modal therapy suggesting that they could potentially be candidates for treatment intensification and/or enrollment in clinical trials of novel therapy.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Nguyen PL, Martin NE, Choeurng V, et al. Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2017. PMID: 28117383. doi:10.1038/pcan.2016.58

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。